5/2
07:08 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $50.00 price target on the stock.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $50.00 price target on the stock.
4/1
05:00 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Medium
Report
Spyre Therapeutics Announces Grants of Inducement Awards
3/26
08:13 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Stifel Nicolaus from $36.00 to $54.00. They now have a "buy" rating on the stock.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Stifel Nicolaus from $36.00 to $54.00. They now have a "buy" rating on the stock.
3/18
08:00 am
syre
Spyre Therapeutics Announces $180 Million Private Placement
High
Report
Spyre Therapeutics Announces $180 Million Private Placement
3/4
10:51 am
syre
Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength [Yahoo! Finance]
High
Report
Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength [Yahoo! Finance]
3/1
05:25 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
High
Report
Spyre Therapeutics Announces Grants of Inducement Awards
3/1
08:42 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $35.00 price target on the stock, up previously from $12.00.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $35.00 price target on the stock, up previously from $12.00.
2/29
04:51 pm
syre
Spyre Therapeutics Inc (SYRE) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Spyre Therapeutics Inc (SYRE) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
2/29
04:13 pm
syre
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/29
04:05 pm
syre
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Medium
Report
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2/26
07:45 am
syre
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference [Yahoo! Finance]
Low
Report
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference [Yahoo! Finance]
2/26
07:30 am
syre
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
Low
Report
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
2/8
07:35 am
syre
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation [Yahoo! Finance]
Low
Report
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation [Yahoo! Finance]
2/8
07:30 am
syre
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
Low
Report
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
2/6
11:34 am
syre
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
Low
Report
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
2/5
07:30 am
syre
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
Low
Report
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
2/2
05:30 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Low
Report
Spyre Therapeutics Announces Grants of Inducement Awards